Distribuzione geografica
Continente #
NA - Nord America 3931
EU - Europa 641
AS - Asia 312
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 4892
Nazione #
US - Stati Uniti d'America 3922
UA - Ucraina 167
IT - Italia 160
CN - Cina 149
DE - Germania 92
IE - Irlanda 72
VN - Vietnam 64
IN - India 56
SE - Svezia 39
BE - Belgio 30
TR - Turchia 27
GB - Regno Unito 22
FI - Finlandia 18
RO - Romania 13
CA - Canada 9
IR - Iran 9
RU - Federazione Russa 7
NL - Olanda 6
PL - Polonia 6
JP - Giappone 5
EE - Estonia 3
EG - Egitto 3
EU - Europa 3
FR - Francia 3
AT - Austria 1
CM - Camerun 1
CZ - Repubblica Ceca 1
ES - Italia 1
KR - Corea 1
MN - Mongolia 1
NG - Nigeria 1
Totale 4892
Città #
Fairfield 716
Chandler 446
Woodbridge 346
Seattle 293
Ashburn 270
Houston 262
Wilmington 241
Cambridge 227
Ann Arbor 207
Dearborn 115
Jacksonville 98
Princeton 76
Beijing 69
Dublin 67
Dong Ket 64
Udine 51
San Diego 39
Brussels 28
Izmir 27
Martignacco 26
Redmond 26
Des Moines 21
Boardman 12
Falls Church 12
Nanjing 12
Norwalk 12
Leawood 10
Timisoara 9
Hefei 8
Phoenix 8
Augusta 7
Jinan 6
Trieste 6
Warsaw 6
Kunming 5
Scafati 5
Simi Valley 5
Ardabil 4
London 4
Menlo Park 4
Nanchang 4
Redwood City 4
Rome 4
Shenzhen 4
Cairo 3
Caserta 3
Dallas 3
Fuzhou 3
Grafing 3
Hebei 3
Montréal 3
New York 3
Nutley 3
Paris 3
San Mateo 3
Shanghai 3
Tallinn 3
Tokyo 3
Toronto 3
Wuhan 3
Castelfranco Veneto 2
Chengdu 2
Curno 2
Fremont 2
Guangzhou 2
Hangzhou 2
Jinhua 2
Monmouth Junction 2
Montreal 2
Philadelphia 2
Sagrado 2
Saint Petersburg 2
Shenyang 2
Waanrode 2
Xian 2
Andover 1
Arezzo 1
Asti 1
Bangalore 1
Bari 1
Buffalo 1
Changsha 1
Chaoyang 1
Chicago 1
Cincinnati 1
Cinisello Balsamo 1
Evanston 1
Florence 1
Genova 1
Gunzenhausen 1
Harbin 1
Helsinki 1
Kashan 1
Langfang 1
Lendinara 1
Madrid 1
Maniago 1
Maserada Sul Piave 1
Melfi 1
Mortegliano 1
Totale 3969
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 165
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 132
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 125
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 118
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 115
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 112
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 108
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 108
Pattern of metastasis and outcome in patients with breast cancer 108
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 105
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 101
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 100
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 100
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 99
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 98
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 97
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 93
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 91
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 88
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 88
Determinants of Last-line Treatment in Metastatic Breast Cancer 87
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 87
Do platinum salts fit all triple negative breast cancers? 87
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 84
null 84
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 83
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 82
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 82
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 81
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 81
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 81
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 80
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 76
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 74
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 73
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 72
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 72
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 70
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 69
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 68
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 67
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 67
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 64
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 64
Risk factors and survival outcomes in patients with brain metastases from breast cancer 63
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 62
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 60
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 57
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 54
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 54
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 50
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 49
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 49
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 49
Time to surgery after neoadjuvant chemotherapy for early breast cancer 47
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 44
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 44
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 43
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 40
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 38
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 30
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 29
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 27
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 25
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 25
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 24
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 24
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 21
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 19
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 19
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 19
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 19
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools 15
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 15
Landscape of circulating tumour DNA in metastatic breast cancer 14
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 13
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study 9
The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer 8
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 8
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 7
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 4
Totale 5163
Categoria #
all - tutte 9877
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9877

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201820 0000 00 00 8093
2018/2019343 131145 50 842 44112585
2019/20201682 5710460214 140216 188176 2061738959
2020/20211306 5213191229 11472 85143 8169108131
2021/2022753 88691514 1440 4625 2010722194
2022/2023838 8710028120 96210 681 110000
Totale 5163